carboplatin,gemcitabine,paclitaxel,vinorelbine,cisplatin,nivolumab,docetaxel,pemetrexed,ipilimumab,pembrolizumab
merck,bms
[]
 one virtually sure thing is that health economics will favor neoadj alone and outside of the us it s relatively unlikely adjuvant will be reimbursed unless the benefit for non-pcr with adjuvant becomes really marked.
Lung cancer & Mesothelioma @HopkinsThoracic @HopkinsKimmel Immunotherapy believer. 🇮🇪 🇺🇸